CHOP is the standard regimen in patients ≤ 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 27-34

  Tirelli, U ^a   Errante, D ^a   Van Glabbeke, M ^a   Teodorovic, I ^a   Kluin Nelemans, J C ^a   Thomas, J ^a   Bron, D ^a   Rosti, G ^a   Somers, R ^a   Zagonel, V ^a   Noordijk, E M ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; VINCRISTINE;

AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTROINTESTINAL TOXICITY; GERIATRICS; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0004815869     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.27     Document Type: Article

References (31)

1. Tirelli U, Zagonel V, Serraino D, et al: Non-Hodgkin's lymphoma in 137 patients aged 70 years or older. A retrospective European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group study. J Clin Oncol 6:1708-1713, 1988
2. Dixon DO, Neilan B, Jones SE, et al: Effect of age on therapeutic outcome in advanced diffuse histocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 4:295-305, 1986
3. Solal-Celigny P, Chastang C, Herrera A, et al: Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am J Med 83:1075-1079, 1987
4. Vose JM, Armitage JO, Weisenburger DD, et al: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 6:1838-1844, 1988
5. Shipp MA, Harrington DP, Anderson JR, et al: A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
6. Armitage JO, Potter JF: Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. Increased complications of advancing age. J Am Geriatr Soc 32:269-273, 1984
7. Miller TP, Jones SE: Initial chemotherapy for clinically localized lymphomas of unfavorable histology. Blood 62:413-418, 1983
8. Brice P, Lepage E, Gisselbrecht C, et al: Aggressive non-Hodgkin lymphoma in the elderly. A retrospective study of 72 patients with clinical features and treatment. Nouv Rev Fr Hematol 32:153-157, 1990
9. Zagonel V, Carbone A, Kerpel-Fronius S, et al: Management of non-Hodgkin's lymphomas in the elderly patients: Conclusions of the Second Intercity Meeting of the European School of Oncology (ESO), 1987 in Monfardini S (ed): The Management of Non-Hodgkin's Lymphomas in Europe. Berlin, Germany, Springer-Verlag, 1990, pp 35-44
10. Carbone A, Volpe R, Gloghini, A, et al: Non-Hodgkin's lymphoma in the elderly: 1. Pathologic features at presentation. Cancer 66:1991-1994, 1990
11. Tirelli U, Carbone A, Zagonel V, et al: Non-Hodgkin's lymphomas in the elderly. Prospective studies with specifically devised chemotherapy regimens in 66 patients. Eur J Cancer Clin Oncol 23:535-540, 1987
12. Zagonel V, Tirelli U, Carbone A, et al: Combination chemotherapy specifically devised for elderly patients with unfavourable nonHodgkin's lymphoma. Cancer Invest 8:575-580, 1990
13. Bonadonna G, Viviani S, Valagussa P, et al: Third line salvage chemotherapy in Hodgkin's disease. Semin Oncol 12:23-25, 1985 (suppl)
14. Landys KE: Mitoxantrone in combination with prednimustine in the treatment of unfavorable non-Hodgkin lymphoma. Invest New Drugs 6:105-113, 1988
15. Tirelli U, Zagonel V, Errante D, et al: A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol 10:228-236, 1992
16. National Cancer Institute Update: Annual Cancer Statistics Update Bethesda, MD, National Cancer Institute, December 8, 1986
17. Holmes FF: Clinical evidence for change in tumor aggressiveness with age, in Balducci L, Lyman GH, Ershler WB (eds): Geriatric Oncology. Philadelphia, PA, Lippincott, 1992, pp 86-91
18. Rosenberg SA, Berard CW, Brown BWJ, et al: National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
19. Ballester OF, Moscinski L, Spiers A, et al: Non-Hodgkin's lymphoma in the older person: A review. J Am Geriatr Soc 41:1245-1254, 1993
20. Phuphanich S, Werner M, Lyman G: Increasing incidence of primary central nervous system lymphoma (PCNSL) in the elderly: Florida Cancer Data Systems (FCDS). Proc Am Soc Clin Oncol 14:185, 1995 (abstr)
21. Sonneveld P, Michiels JJ: Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: A feasibility study using a mitoxantrone containing regimen. Br J Cancer 62:105-108, 1990
22. O'Reilly SE, Klimo P, Connors JM: Low-dose ACOP-B and VABE: Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 9:741-747, 1991
23. Coiffier B, Biron P, Bastion Y, et al: Elderly lymphoma patients have a long survival if treated with curative intent. A study from the G.E.L.A. on 453 patients older than 69 years. Proc Am Soc Clin Oncol 15:417, 1996 (abstr 1279)
24. Meyer RM, Browman GP, Samosh ML, et al: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly-patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386-2393, 1995
25. Sonneveld P, de Ridder M, van der Lelie H, et al: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13:2530-2539, 1995
26. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
27. Martelli M, Guglielmi C, Coluzzi S, et al: P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 11:2362-2369, 1993
28. O'Reilly SE, Connors JM, Howdle S, et al: In search of an optimal regimen for elderly patients with advanced-stage diffuse He-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 11:2250-2257, 1993
29. McMaster ML, Johnson DH, Greer JP, et al: A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 67:1487-1492, 1991
30. Goss P, Burkes R, Rudinskas L, et al: A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients. Leuk Lymphoma 18:145-152, 1995
31. Posner LE, Dukart G, Goldberg J, et al: Mitoxantrone: An overview of safety and toxicity. Invest New Drugs 3:123-132, 1985